Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study - 06/12/21
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 9 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Abstract |
Background |
Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Methods |
Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method.
Results |
A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P<0.001) but not with brain metastasis (HR=1.67, P=0.278).
Conclusions |
This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Non-small cell lung cancer, Erlotinib, EGFR-TKI, Progression-free survival, Overall survival
Abbreviations : GH, PS, CCTIRS, CI, CPHG, CNIL, CTCAE, EGFR, HR, IFCT, INCa, KBP-2010-CPHG, OS, NSCLC, PFS, RCT, SCLC, SD, TKI, TNM
Mappa
Vol 80
Articolo 100795- novembre 2021 Ritorno al numero
Articolo precedente
- Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months
- E. Noel-Savina, T. Viatgé, G. Faviez, B. Lepage, L.t Mhanna, S. Pontier, M. Dupuis, S. Collot, P. Thomas, J. Idoate Lacasia, L. Crognier, S. Bouharaoua, S. Silva Sifontes, J. Mazieres, G. Prévot, A. Didier
- Coping strategies, anxiety and depression related to the COVID-19 pandemic in lung transplant candidates and recipients. Results from a monocenter series
- Alice Savary, Malika Hammouda, Lucie Genet, Cendrine Godet, Vincent Bunel, Gaelle Weisenburger, Tiphaine Goletto, Chahine Medraoui, Gilles Jebrak, Armelle Marceau, Alexy Tran-Dinh, Pierre Mordant, Yves Castier, Philippe Montravers, Herve Mal, Jonathan Messika, for the Bichat Lung Transplant Group
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?